Trust Blue Horizon Enterpri... Net Worth

The estimated Net Worth of Trust Blue Horizon Enterpri... is at least $273 Milhão dollars as of 17 April 2024. Trust Enterpri owns over 3,600,000 units of Stoke Therapeutics stock worth over $159,835,858 and over the last 2 years Trust sold STOK stock worth over $112,926,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Trust Enterpri STOK stock SEC Form 4 insiders trading

Trust has made over 2 trades of the Stoke Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Trust sold 3,600,000 units of STOK stock worth $41,760,000 on 17 April 2024.

The largest trade Trust's ever made was selling 3,600,000 units of Stoke Therapeutics stock on 17 April 2024 worth over $41,760,000. On average, Trust trades about 2,618,000 units every 251 days since 2022. As of 17 April 2024 Trust still owns at least 10,843,681 units of Stoke Therapeutics stock.

You can see the complete history of Trust Enterpri stock trades at the bottom of the page.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., eTrust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.

What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Complete history of Trust Enterpri stock trades at Akero Therapeutics Inc e Stoke Therapeutics

Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include:

• Stephen Tulipano,
  Chief Financial Officer
• Dr. Edward M. Kaye,
  CEO & Director
• Dr. Edward M. Kaye M.D., Ph.D.,
  CEO & Director
• Huw Nash,
  Chief Operating Officer, Chief Business Officer
• Barry Ticho,
  Chief Medical Officer
• Edward Kaye,
  Chief Executive Officer, Director
• Dr. Barry S. Ticho FACC, M.D., Ph.D.,
  Chief Medical Officer
• Stephen J. Tulipano CPA, CPA, MBA,
  Chief Financial Officer
• Seth Harrison,
  Independent Chairman of the Board
• Jennifer Burstein,
  Independent Director
• Adrian Krainer,
  Independent Director
• Arthur Tzianabos,
  Independent Director
• Arthur Levin,
  Independent Director
• Dr. Adrian R. Krainer Ph.D.,
  Co-Founder, Independent Director & Member of Scientific Advisory Board
• Garry Menzel,
  Independent Director
• Julie Smith,
  Independent Director
• Gene Liau,
  Executive Vice President, Head of Research and Preclinical Development
• Dawn Kalmar,
  Chief Communications Officer
• Jonathan Allan J.D.,
  Deputy Gen. Counsel
• Dr. Gene Liau,
  Chief Scientific Officer
• Dr. Huw M. Nash Ph.D.,
  COO & Chief Bus. Officer
• Nancy M. Wyant,
  VP & Head of Clinical Operations
• Shamim Ruff,
  Chief Regulatory Officer
• Joan Wood,
  Head of HR
• Isabel Aznarez Ph.D.,
  Co-Founder, VP & Head of Biology
• Group, Llc Green Jeremy Red...,
  
• Samuel W. Hall,
  Director
• Life Science Ventures, L.P....,
  
• Investments, Lpwong Roderic...,
  
• Robin A. Walker,
  Chief Legal Officer, CCO & Sec
• Jonathan Allan,
  GENERAL COUNSEL & CORP SEC
• Trust Blue Horizon Enterpri...,
  
• Thomas Leggett,
  Chief Financial Officer
• Ian F Smith,